These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34545083)

  • 1. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B.
    Deng MY; Sturm D; Pfaff E; Sill M; Stichel D; Balasubramanian GP; Tippelt S; Kramm C; Donson AM; Green AL; Jones C; Schittenhelm J; Ebinger M; Schuhmann MU; Jones BC; van Tilburg CM; Wittmann A; Golanov A; Ryzhova M; Ecker J; Milde T; Witt O; Sahm F; Reuss D; Sumerauer D; Zamecnik J; Korshunov A; von Deimling A; Pfister SM; Jones DTW
    Nat Commun; 2021 Sep; 12(1):5530. PubMed ID: 34545083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
    Barrow J; Adamowicz-Brice M; Cartmill M; MacArthur D; Lowe J; Robson K; Brundler MA; Walker DA; Coyle B; Grundy R
    Neuro Oncol; 2011 Feb; 13(2):212-22. PubMed ID: 21138945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic landscape of gliomas arising after therapeutic radiation.
    López GY; Van Ziffle J; Onodera C; Grenert JP; Yeh I; Bastian BC; Clarke J; Oberheim Bush NA; Taylor J; Chang S; Butowski N; Banerjee A; Mueller S; Kline C; Torkildson J; Samuel D; Siongco A; Raffel C; Gupta N; Kunwar S; Mummaneni P; Aghi M; Theodosopoulos P; Berger M; Phillips JJ; Pekmezci M; Tihan T; Bollen AW; Perry A; Solomon DA
    Acta Neuropathol; 2019 Jan; 137(1):139-150. PubMed ID: 30196423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma.
    DeSisto J; Lucas JT; Xu K; Donson A; Lin T; Sanford B; Wu G; Tran QT; Hedges D; Hsu CY; Armstrong GT; Arnold M; Bhatia S; Flannery P; Lemma R; Hardie L; Schüller U; Venkataraman S; Hoffman LM; Dorris K; Mulcahy Levy JM; Hankinson TC; Handler M; Liu AK; Foreman N; Vibhakar R; Jones K; Allen S; Zhang J; Baker SJ; Merchant TE; Orr BA; Green AL
    Nat Commun; 2021 Sep; 12(1):5531. PubMed ID: 34545084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis.
    Chen D; Persson A; Sun Y; Salford LG; Nord DG; Englund E; Jiang T; Fan X
    PLoS One; 2013; 8(4):e61556. PubMed ID: 23630597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
    Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
    Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
    Paugh BS; Qu C; Jones C; Liu Z; Adamowicz-Brice M; Zhang J; Bax DA; Coyle B; Barrow J; Hargrave D; Lowe J; Gajjar A; Zhao W; Broniscer A; Ellison DW; Grundy RG; Baker SJ
    J Clin Oncol; 2010 Jun; 28(18):3061-8. PubMed ID: 20479398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
    Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
    PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.
    Martinho O; Longatto-Filho A; Lambros MB; Martins A; Pinheiro C; Silva A; Pardal F; Amorim J; Mackay A; Milanezi F; Tamber N; Fenwick K; Ashworth A; Reis-Filho JS; Lopes JM; Reis RM
    Br J Cancer; 2009 Sep; 101(6):973-82. PubMed ID: 19707201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
    Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
    Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
    Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
    Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
    Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
    Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.
    Sun Y; Zhang W; Chen D; Lv Y; Zheng J; Lilljebjörn H; Ran L; Bao Z; Soneson C; Sjögren HO; Salford LG; Ji J; French PJ; Fioretos T; Jiang T; Fan X
    Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3538-43. PubMed ID: 24550449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
    Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
    Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.